Cell Reports · 2014 · 116 citations · 47 references
MedicineCancer BiologyOncologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingCancer ProgressionMalignant NeoplasmsProtein Kinase CascadesSignal Transduction In CancerTumor Suppressor GenesCancer Signaling PathwaysErk SignalingMapk SignalingMitogen-activated Protein Kinase Pathway ActivationRaf-mek-erk SignalingRas-mitogen-activated Protein Kinase SignalingTumor Suppressor LossTumor Suppressor Pathways
The kinase Mnk2 is a substrate of the MAPK pathway and phosphorylates the translation initiation factor eIF4E. In humans, MKNK2, the gene encoding for Mnk2, is alternatively spliced yielding two splicing isoforms with differing last exons: Mnk2a, which contains a MAPK-binding domain, and Mnk2b, which lacks it. We found that the Mnk2a isoform is downregulated in breast, lung, and colon tumors and is tumor suppressive. Mnk2a directly interacts with, phosphorylates, activates, and translocates p38α-MAPK into the nucleus, leading to activation of its target genes, increasing cell death and suppression of Ras-induced transformation. Alternatively, Mnk2b is pro-oncogenic and does not activate p38-MAPK, while still enhancing eIF4E phosphorylation. We further show that Mnk2a colocalization with p38α-MAPK in the nucleus is both required and sufficient for its tumor-suppressive activity. Thus, Mnk2a downregulation by alternative splicing is a tumor suppressor mechanism that is lost in some breast, lung, and colon tumors.
47
The gene encoding the splicing factor SF2/ASF is a proto-oncogene
Rotem Karni, Elisa de Stanchina, Scott W. Lowe et al. · Nature Structural & Molecular Biology · 2007 · 937 citations